Johnson & Johnson (JNJ)

126.26
0.99 0.78
NYSE : Health Care
Prev Close 127.25
Open 127.05
Day Low/High 126.21 / 127.65
52 Wk Low/High 107.05 / 129.00
Volume 10.26M
Avg Volume 7.03M
Exchange NYSE
Shares Outstanding 2.71B
Market Cap 347.18B
EPS 6.00
P/E Ratio 21.60
Div & Yield 3.20 (2.50%)

Latest News

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #21 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #347 spot.

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

The top 64 companies taking a trip to TheStreet's 2017 Market Bracket Challenge tournament.

Johnson & Johnson Names Winners Of First Africa Innovation Challenge

Johnson & Johnson Names Winners Of First Africa Innovation Challenge

Competition Part of Company's Eighty-Five Year Commitment to Supporting Entrepreneurs, Science Education Opportunities, and Health Systems Across the Continent

Ortho Clinical Diagnostics Announces Expansion Of Global Agreement With Astute Medical For NephroCheck Test

Ortho Clinical Diagnostics Announces Expansion Of Global Agreement With Astute Medical For NephroCheck Test

Agreement gives Ortho expanded distribution rights in Europe for the NephroCheck Test on the Astute140 platform

Who Are the Best Employers for Working Mothers?

Who Are the Best Employers for Working Mothers?

Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.

The 10 Most Important Tips for Playing the Stock Market in March

The 10 Most Important Tips for Playing the Stock Market in March

Where should you put your money in March? TheStreet has the strategies and analysis to help guide your investment moves for the month.

Trump Tax Plan Could Make Gold Great Again

Trump Tax Plan Could Make Gold Great Again

Bigger deficits will only add to inflationary pressures, boosting precious metals.

A Lesson on the Importance of Cash

To put it simply, Stanley Black & Decker and Thermo Fisher screwed up.

Johnson & Johnson to Close UK Plant

Johnson & Johnson to Close UK Plant

The closure of the plant threatens roughly 400 jobs.

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.

Cramer: Top 10 Bull Markets Right Now (Part 1)

Cramer: Top 10 Bull Markets Right Now (Part 1)

Bull market number one, perhaps of all time: the financials.

Why Trump's Tax Plan Should Boost the Russell 2000

Why Trump's Tax Plan Should Boost the Russell 2000

Small-caps love lower corporate taxes and higher import duties.

Cramer: Top 10 Bull Markets Right Now

Cramer: Top 10 Bull Markets Right Now

Bull market number one, perhaps of all time: the financials.

Trump Tax Cuts Could Actually Weaken the Dollar

Trump Tax Cuts Could Actually Weaken the Dollar

Forex markets are wrong to bet on a stimulus-strengthened greenback.

How Income Investors Should Play Trump's Tax Plan

How Income Investors Should Play Trump's Tax Plan

Look for big discounts to NAV in closed-end muni bonds.

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'

Johnson & Johnson Wins Fourth Lawsuit Tied to Talcum Powder

Johnson & Johnson Wins Fourth Lawsuit Tied to Talcum Powder

Johnson & Johnson had lost its three previous cases involving the product.

Tech Stocks Under Trump

Tech Stocks Under Trump

They might have an issue with corporate tax reform.

We Probably Won't See a Tax Bill in March, but We Might Get Some Hints

We Probably Won't See a Tax Bill in March, but We Might Get Some Hints

Despite what bullish Wall Street investors seem to believe, sweeping tax reform isn't on the immediate horizon. But we might soon get more guidance.

Johnson & Johnson Becomes #20 Most Shorted Dow Stock, Replacing Cisco Systems

Johnson & Johnson Becomes #20 Most Shorted Dow Stock, Replacing Cisco Systems

The most recent short interest data has been released for the 02/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Jim Cramer Is Passing on Valeant Ahead of Earnings

Jim Cramer Is Passing on Valeant Ahead of Earnings

Jim Cramer is opting for stocks like Allergan and Johnson & Johnson over Valeant Pharmaceuticals.

Johnson & Johnson Transparency Report Shows 3.5% Increase in Drug Prices

Johnson & Johnson Transparency Report Shows 3.5% Increase in Drug Prices

Johnson & Johnson (JNJ) plans to issue a transparency report annually going forward.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.

Ortho Clinical Diagnostics Awarded Top Honor For Global Excellence In Customer Service

Ortho Clinical Diagnostics Awarded Top Honor For Global Excellence In Customer Service

Ortho Care™ Support Program Recognized As Best-in-Class Service and Support for Hospitals, Hospital Networks, Blood Banks and Labs

Johnson & Johnson Completes Acquisition Of Abbott Medical Optics

Johnson & Johnson Completes Acquisition Of Abbott Medical Optics

Johnson & Johnson Vision will reach more patients globally with expansion into cataract surgery